Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
1(8%)
Results Posted
22%(2 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_2
2
17%
Ph phase_4
1
8%
Ph phase_3
6
50%
Ph not_applicable
1
8%

Phase Distribution

0

Early Stage

2

Mid Stage

7

Late Stage

Phase Distribution10 total trials
Phase 2Efficacy & side effects
2(20.0%)
Phase 3Large-scale testing
6(60.0%)
Phase 4Post-market surveillance
1(10.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

12

all time

Status Distribution
Active(1)
Completed(9)
Terminated(1)
Other(1)

Detailed Status

Completed9
Recruiting1
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
1
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (20.0%)
Phase 36 (60.0%)
Phase 41 (10.0%)
N/A1 (10.0%)

Trials by Status

recruiting18%
terminated18%
completed975%
unknown18%

Recent Activity

1 active trials
Showing 5 of 12
recruitingphase_3

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

NCT03678025
completed

Exogenous Sex Hormones and PONV

NCT06816355
completedphase_2

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

NCT02058706
completed

Malignant Testicular Tumors in Children: A Single Institution's 12-year Experience

NCT04826952
completedphase_3

Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer

NCT00104715
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT03678025Phase 3

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Recruiting
NCT06816355

Exogenous Sex Hormones and PONV

Completed
NCT02058706Phase 2

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

Completed
NCT04826952

Malignant Testicular Tumors in Children: A Single Institution's 12-year Experience

Completed
NCT00104715Phase 3

Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer

Completed
NCT00002633Phase 3

Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer

Completed
NCT00081159Phase 2

Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases

Completed
NCT01750632Not Applicable

Subcapsular Orchiectomy in Men With Klinefelter Syndrome

Completed
NCT02102646Phase 4

MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism

Completed
NCT00110162Phase 3

Androgen Deprivation Therapy in Treating Patients With Prostate Cancer

Unknown
NCT00014586Phase 3

Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer

Terminated
NCT00002881Phase 3

Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer

Completed

All 12 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
12